Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis

Background: The clinical-stage drug candidate EBL-1003 (apramycin) represents a distinct new subclass of aminoglycoside antibiotics for the treatment of drug-resistant infections. It has demonstrated best-in-class coverage of resistant isolates, and preclinical efficacy in lung infection models. How...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Katja Becker, Sha Cao, Anna Nilsson, Maria Erlandsson, Sven-Kevin Hotop, Janis Kuka, Jon Hansen, Klara Haldimann, Solveiga Grinberga, Talia Berruga-Fernández, Douglas L. Huseby, Reza Shariatgorji, Evelina Lindmark, Björn Platzack, Erik C. Böttger, David Crich, Lena E. Friberg, Carina Vingsbo Lundberg, Diarmaid Hughes, Mark Brönstrup, Per E. Andrén, Edgars Liepinsh, Sven N. Hobbie
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
R
Acceso en línea:https://doaj.org/article/b25c8a267d4642389bf6d5a2908a5a98
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!